-  INCLUSION CRITERIA:

               1. Pathologically confirmed malignancy for which high-dose rate brachytherapy is
                  appropriate as a component of their therapeutic regimen.

               2. Age greater than 18 years of age.

               3. ECOG performance status of 0, 1, or 2.

               4. Participant must have a primary medical or surgical oncologist in the community
                  or at NCI who is willing to collaborate with the ROB staff in the clinical
                  management of the participant.

               5. Participants of childbearing or child- fathering potential must be willing to use
                  a medically acceptable form of birth control, which includes abstinence, while
                  they are being treated on this study.

               6. Site-specific inclusion criteria (any one or more of the following):

        Gynecologic Cancers:

        Endometrial cancer

          -  Participants at a higher risk of recurrence (because of either grade, myometrial
             invasion, lymphatic vascular space invasion, tumor size, lymph node status, tumor
             extension, presence or absence of surgical staging)

          -  Participants who have suffered a recurrence at the vaginal cuff

          -  Participants who are unable to undergo surgery and must have treatment for an
             inoperable primary endometrial cancer.

        Cervical cancer

          -  Participants who are unable to undergo surgery and must have treatment for an
             inoperable primary cervical cancer.

          -  Participants with locally advanced cervical cancer in whom brachytherapy will be
             integrated as a boost to external beam radiation either in a palliative or curative
             setting (definitive or post-operative setting).

        Lung cancer

          -  Participants with an endobronchial component causing symptoms

          -  Participants who can not undergo resection because of poor lung function or distant
             lung metastasis

        Breast cancer

          -  Infiltrating ductal carcinoma or DCIS, stage T0, T1, and T2 less than or equal to 3.0
             cm, N0 and M0,

          -  Participants benefiting from HDR as either as a boost or accelerated partial breast
             irradiation regimen.

        Prostate Cancer

        -Participants with localized prostate cancer (T1b-T3b) in whom brachytherapy will be
        integrated as a boost to external beam radiation or used as monotherapy for definitive
        management.

        EXCLUSION CRITERIA:

          1. Cognitively impaired participants who cannot give informed consent.

          2. Participants currently receiving concurrent investigational chemotherapeutic agents.

          3. Participants receiving concomitant chemotherapy administration in the 5 days preceding
             brachytherapy (except for gynecological cancer patients who may have received
             concurrent chemotherapy as a component of their treatment regimen)

          4. Pregnant or breast-feeding females are excluded because of the potential mutagenic
             effects on a developing fetus or newborn.

          5. Clinically significant unrelated systemic illness (serious infections or significant
             cardiac, pulmonary, hepatic or other organ dysfunction), which in the judgment of the
             Principal or Associate Investigator would compromise the participant s ability to
             tolerate this therapy or are likely to interfere with the study procedures or results.

          6. Participants who are in the estimation of the PI, deemed unable or unlikely to adhere
             to protocol treatment.

          7. Abnormal bleeding times or active anti-coagulation therapy.

               -  platelets less than 100,000 per mm(3)

               -  PT/PTT greater than 1.5 the upper normal limit (UNL)

          8. Any participant or tumor/anatomical factors that may prevent brachytherapy apparatus
             from being properly and safely inserted and positioned and from radiation therapy
             being administered per ABS guidelines.

          9. Participants whose malignancy has one or more of the following site-specific criteria
             disqualifying them from the study:

        1. Breast cancer:

          -  Participants inappropriate for standard breast conservation therapy (Multicentric
             disease, inability to achieve clear margins);

          -  male participants with breast cancer

          -  autoimmune disorders, including SLE, Scleroderma, etc

          -  distant metastases;

             2. Prostate cancer:

          -  distant metastases

          -  lymph node metastases